Luther King Capital Management (LKCM)
UTHR icon

Luther King Capital Management (LKCM)’s United Therapeutics UTHR Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,500
Closed -$276K – 631
2013
Q3 		$276K Sell
3,500
-5,030
-59% -$368K ﹤0.01% 617
2013
Q2 		$561K Buy
+8,530
New +$549K 0.01% 519

Other funds holding UTHR

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Herndon Capital Management Atlanta, Georgia $659M AUM 22.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Luther King Capital Management (LKCM)'s UTHR Position: Q4 2013 in Review

Luther King Capital Management (LKCM) sold out of United Therapeutics (UTHR) in Q4 2013, closing a stake of 3,500 shares — an estimated $276K sold.

Luther King Capital Management (LKCM) first reported a position in UTHR in Q2 2013 and held it in 2 quarters. The position peaked at $561K in Q2 2013. 321 funds tracked by Wall St. Rank hold UTHR as of Q4 2013.

  • Luther King Capital Management (LKCM) reported no remaining United Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 3,500 United Therapeutics shares in Q4 2013, an estimated $276K.
  • Luther King Capital Management (LKCM) first reported a position in United Therapeutics in Q2 2013 and held it in 2 quarters.
  • Luther King Capital Management (LKCM)'s United Therapeutics position peaked at $561K in Q2 2013.
  • 321 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2013.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q4 2013, filed 12 Feb 2014.